CERC - Cerecor Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.8300
-0.1100 (-2.79%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.9400
Open3.9000
Bid3.7600 x 1000
Ask3.9500 x 1400
Day's Range3.7600 - 3.9200
52 Week Range2.9100 - 7.6500
Volume52,890
Avg. Volume102,098
Market Cap270.966M
Beta (5Y Monthly)2.27
PE Ratio (TTM)N/A
EPS (TTM)-0.4720
Earnings DateMar 15, 2020 - Mar 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.75
  • Drugmakers raised prices of over 40 prescription drugs
    Yahoo Finance Video

    Drugmakers raised prices of over 40 prescription drugs

    Yahoo Finance’s Adam Shapiro, Sibile Marcellus, and Rick Newman join Direxion Managing Director Sylvia Jablonski to discuss.

  • Done deal: Maryland biopharm firm completes acquisition of Aevi Genomic Medicine
    American City Business Journals

    Done deal: Maryland biopharm firm completes acquisition of Aevi Genomic Medicine

    The CEO of Wayne-based Aevi is taking over as CEO of the combined company focused on rare pediatric diseases.

  • GlobeNewswire

    Cerecor and Aevi Genomic Medicine Complete Merger

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today it has completed the previously announced acquisition of Aevi Genomic Medicine (GNMX) in an all-stock transaction valued at approximately $15.6 million at close, plus contingent value rights (CVRs) for up to an additional $6.5 million in subsequent payments based on clinical and/or regulatory milestones. Cerecor’s pipeline now includes six clinical-stage assets, accelerating the Company’s transformation into a research and development organization focused on developing new medicines for unmet needs in rare diseases, particularly for pediatric patients.

  • Is Cerecor Inc. (CERC) A Good Stock To Buy?
    Insider Monkey

    Is Cerecor Inc. (CERC) A Good Stock To Buy?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • CERC: Expansion in Rare and Orphan Diseases with Acquisition of Aevi Genomic Medicine…
    Zacks Small Cap Research

    CERC: Expansion in Rare and Orphan Diseases with Acquisition of Aevi Genomic Medicine…

    By David Bautz, PhD NASDAQ:CERC READ THE FULL CERC RESEARCH REPORT Business Update Acquisition of Aevi Genomic Medicine Strengthens Rare and Orphan Disease Pipeline On December 5, 2019, Cerecor, Inc. (NASDAQ:CERC) announced the acquisition of Aevi Genomic Medicine (GNMX) in an all-stock transaction valued at approximately $16.1 million plus contingent value rights (CVRs) for up to an additional

  • ACCESSWIRE

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Aevi Genomic Medicine, Inc. to Independent Bank Group Inc. is Fair to Shareholders

    NEW YORK, NY / ACCESSWIRE / December 10, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Aevi Genomic Medicine, Inc. ("Aevi" ...

  • GlobeNewswire

    Cerecor to Acquire Aevi Genomic Medicine

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan and rare diseases, as well as neurology announced today it has entered into a definitive merger agreement to acquire Aevi Genomic Medicine (GNMX) in an all-stock transaction valued at approximately $16.1 million at closing, plus contingent value rights, or CVRs, for up to an additional $6.5 million in subsequent milestone payments on clinical or regulatory successes, or both. Additionally, the Company is exploring strategic alternatives for its neurological assets as well as its one commercialized product Millipred®.

  • GlobeNewswire

    Cerecor Reports Third Quarter 2019 Results

    Sale of Pediatric Portfolio in a Deal Valued in Excess of $43 MillionFirst Patient Enrolled in Diabetic OH Trial with CERC-301Completed Phase 1 Healthy Volunteer Study with.

  • GlobeNewswire

    Cerecor Announces Clinical Updates on CERC-301 and CERC-802

    - CERC-301 Enrolls First Patient in Diabetic Orthostatic Hypotension Trial -CERC-802 Completes Phase I Safety Study in Healthy Volunteers ROCKVILLE, Md., Nov. 11, 2019 --.

  • GlobeNewswire

    Cerecor Closes Deal to Sell Pediatric Portfolio

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and neurology, announced today that it has closed the sale of its pediatric portfolio of assets with AYTU BioScience, Inc. (“AYTU”) in a deal valued in excess of $43 million including the assumption of various liabilities and product-related obligations. The consideration includes a combination of cash and Aytu preferred stock (the “shares”) totaling $17 million and the assumption of Cerecor’s outstanding payment obligations payable to Deerfield CSF, LLC in the amount of $15 million (“Deerfield Note”) and certain other liabilities in excess of $11 million, providing non-dilutive cash generation for Cerecor.

  • Cerecor (NASDAQ:CERC) Is Making Moderate Use Of Debt
    Simply Wall St.

    Cerecor (NASDAQ:CERC) Is Making Moderate Use Of Debt

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • GlobeNewswire

    Cerecor To Sell Pediatric Portfolio to AYTU BioScience

    -Deal Valued in Excess of $32 Million-Eliminates Debt Associated with Avadel / Deerfield Agreement-Provides Non-Dilutive Cash Generation to Fund R&D  -Extends Runway Towards.

  • GlobeNewswire

    Cerecor Receives Fast Track Designation from FDA for CERC-802 for the Treatment of Mannose-Phosphate Isomerase Deficiency

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CERC-802, an ultra-pure, oral formulation of D-mannose currently in development for the treatment of Mannose-Phosphate Isomerase Deficiency, also known as MPI-CDG or CDG-1b.

  • GlobeNewswire

    Cerecor Reports Second Quarter 2019 Results

    -Positive Final Results with CERC-301 in nOH-First Patient Enrolled in CDG FIRST Trial- FDA Acceptance of IND Application of CERC-802 ROCKVILLE, Md., Aug. 08, 2019 -- Cerecor.

  • GlobeNewswire

    FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-802 for the treatment of MPI-CDG

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has received notification from the U.S. Food and Drug Administration (FDA), stating that the FDA has accepted the CERC-802 MPI deficiency Investigational New Drug (IND) application filing and the proposed study can begin immediately. CERC-802, an ultra-pure, oral formulation of D-mannose is currently in development for the treatment of Mannose Phosphate Isomerase (MPI) Deficiency, also known as MPI-CDG or CDG-1b.

  • What Does Cerecor Inc.'s (NASDAQ:CERC) Balance Sheet Tell Us About It?
    Simply Wall St.

    What Does Cerecor Inc.'s (NASDAQ:CERC) Balance Sheet Tell Us About It?

    While small-cap stocks, such as Cerecor Inc. (NASDAQ:CERC) with its market cap of US$191m, are popular for their...

  • Zacks Small Cap Research

    CERC: CDG FIRST Trial Underway…

    By David Bautz, PhD NASDAQ:CERC READ THE FULL CERC RESEARCH REPORT Business Update CDG FIRST Trial Underway On July 15, 2019, Cerecor Inc. (NASDAQ:CERC) announced the first patient has been enrolled in ...

  • GlobeNewswire

    Cerecor Announces First Patient Enrolled in CDG FIRST Trial

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced it has enrolled its first patient into the CDG FIRST (Congenital Disorders of Glycosylation Formative Retrospective Study) trial. The CDG FIRST trial is a multi-center, international, non-interventional, retrospective study that follows general principles of periodic assessment of CDG patients in routine practice.  The objectives of the study are to collect natural history and treatment-related data of patients diagnosed with PGM1-CDG, MPI-CDG or SLC35C1-CDG who are either treated with or without D-galactose, D-mannose and L-fucose, respectively, as well as patients with other CDGs who are treated with one of the sugars.

  • GlobeNewswire

    Cerecor Announces Positive Final Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (OH)

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive results from its completed Phase I study of CERC-301, being developed for the treatment of neurogenic orthostatic hypotension (nOH).

  • Benzinga

    18 Stocks Joining The Russell Indices

    The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...

  • GlobeNewswire

    Cerecor Added to Russell 3000® Index

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it has been added to the Russell 3000® Index effective after the U.S. market opens on July 1, 2019. Membership in the Russell 3000® Index, which remains in place for one year, means the automatic inclusion of Cerecor’s common stock in index funds designed to track stocks included in the Russell 3000® Index.

  • GlobeNewswire

    Cerecor Appoints Keith Schmidt to its Board of Directors

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced the appointment of Keith Schmidt to its Board of Directors effective immediately.  Mr. Schmidt joins the Cerecor Board as a member of the Audit Committee, the Compensation Committee, and an independent director serving a term ending at the 2019 Annual Meeting.

  • GlobeNewswire

    Cerecor Set to Join Russell 3000® Index

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it is set to join the Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the U.S. market opens on July 1, 2019, according to a preliminary list of additions posted June 7, 2019. Membership in the Russell 3000® Index, which remains in place for one year, means the automatic inclusion of Cerecor’s common stock in index funds designed to track stocks included in the Russell 3000® Index. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

  • Zacks Small Cap Research

    CERC: Completion of Phase 1 Trial of CERC-801…

    On April 29, 2019, Cerecor Inc. (CERC) announced dosing has completed in the Phase 1 clinical trial of CERC-801 (D-galactose), which is being developed for the treatment of Phosphoglucomutase 1 (PGM1) deficiency. The open label, randomized, single dose, 4-way crossover study in 16 healthy adult volunteers showed CERC-801 to be safe and well tolerated with no reports of serious adverse events. The company has also initiated a natural history study to collect efficacy and safety data from CDG patients treated with monosaccharide replacement therapy, which will be an important part of the application for approval using the 505(b)(2) pathway.